[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.141.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 16, 1997

Bioequivalence of Levothyroxine Preparations: Industry Sponsorship and Academic Freedom-Reply

Author Affiliations

Chancellor University of California, San Francisco

JAMA. 1997;277(15):1201. doi:10.1001/jama.1997.03540390031023

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In Reply.  —As industry funding for university research increases in quantity and complexity, it seems inevitable that there will be occasional clashes of culture. The case involving Dr Dong and colleagues is one such unfortunate chapter in the annals of university-industry relations, annals that are otherwise filled with tales of highly innovative and productive collaborations that have delivered enormous benefit to the public and built for our nation a research and development capability that is unmatched among the nations of the world. We must view incidents such as that involving Dong and colleagues as only temporary setbacks and learn from them how we can make our relationships more harmonious and mutually productive. Even the smallest lessons we all continue to learn are too important to ignore.Let me make one comment in response to Mr Eckert's letter. He states, "As a partner in research, we have a responsibility to ensure that work

×